Precipitated kappa-opioid receptor agonist withdrawal increases glutamate in rat locus coeruleus

被引:15
|
作者
Hoshi, K [1 ]
Ma, TG [1 ]
Ho, IK [1 ]
机构
[1] UNIV MISSISSIPPI,MED CTR,DEPT PHARMACOL & TOXICOL,JACKSON,MS 39216
关键词
butorphanol; glutamate; kappa-opioid receptor agonist; Locus coeruleus; microdialysis; U-69,593;
D O I
10.1016/S0014-2999(96)00569-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Extracellular fluid levels of excitatory amino acids (glutamate, Glu; and aspartate, Asp) in the locus coeruleus and the behavioral signs during naloxone-precipitated withdrawal from kappa-opioid receptor agonists, butorphanol and (5 alpha,7 alpha,8 beta)-(+)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]-benzeneacetamide (U-69,593), were investigated by in vivo microdialysis. Increases in levels of Glu, but not of Asp, were noted after naloxone (12 or 48 nmol/5 mu l, locus coeruleus)-precipitated withdrawal in the rats which had been intracerebroventricularly infused with butorphanol (26 nmol/1 mu l/h) or U-69,593 (26 nmol/10 mu l/h) for 3 days. The Glu levels in the locus coeruleus increased following administration of naloxone before and during the first 15-min sample after the precipitation of withdrawal in the butorphanol- or U-69,593-dependent rats. Furthermore, behavioral evidence of withdrawal (teeth-chattering, wet-dog shakes, etc.) was detected following the naloxone challenge in the butorphanol- and U-69,593-infused rats, but not in saline-infused controls. These results provide direct evidence to support the role of excitatory amino acids within the locus coeruleus in butorphanol or U-69,593 withdrawal.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 50 条
  • [32] Locus Coeruleus Kappa-Opioid Receptors Modulate Reinstatement of Cocaine Place Preference Through a Noradrenergic Mechanism
    Ream Al-Hasani
    Jordan G McCall
    Audra M Foshage
    Michael R Bruchas
    Neuropsychopharmacology, 2013, 38 : 2484 - 2497
  • [33] Locus Coeruleus Kappa-Opioid Receptors Modulate Reinstatement of Cocaine Place Preference Through a Noradrenergic Mechanism
    Al-Hasani, Ream
    McCall, Jordan G.
    Foshage, Audra M.
    Bruchas, Michael R.
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 (12) : 2484 - 2497
  • [34] INCREASED KAPPA-OPIOID RECEPTOR-BINDING IN ALZHEIMER LOCUS-CERULEUS
    BURKE, WJ
    GORODINSKY, A
    CHUNG, HD
    SCHMITT, CA
    MILLER, C
    COSCIA, CJ
    NEUROLOGY, 1994, 44 (04) : A389 - A389
  • [35] Ascent of the kappa-opioid receptor in psychopharmacology
    William A. Carlezon
    Klaus A. Miczek
    Psychopharmacology, 2010, 210 : 107 - 108
  • [36] PHARMACOLOGICAL PROPERTIES OF R-84760, A NOVEL KAPPA-OPIOID RECEPTOR AGONIST
    FUJIBAYASHI, K
    SAKAMOTO, K
    WATANABE, M
    IIZUKA, Y
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 261 (1-2) : 133 - 140
  • [37] BIPHASIC EFFECT OF A KAPPA-OPIOID RECEPTOR AGONIST ON PLASMA OXYTOCIN LEVELS IN RATS
    GRELL, S
    FJALLAND, B
    CHRISTENSEN, JD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 166 (01) : 41 - 48
  • [38] KETOCYCLAZOCINE, A KAPPA-OPIOID RECEPTOR AGONIST, AND CONTROL OF INTESTINAL MYOELECTRIC ACTIVITY IN DOGS
    TELFORD, GL
    CAUDILL, A
    CONDON, RE
    SZURSZEWSKI, JH
    AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (05): : G566 - G570
  • [39] Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats
    Riahi, Esmail
    Mirzaii-Dizgah, Iraj
    Karimian, Seyed Morteza
    Roodsari, Hamid Reza Sadeghipour
    Dehpour, Ahmad Reza
    BEHAVIOURAL BRAIN RESEARCH, 2009, 196 (01) : 11 - 14
  • [40] Topical treatment with a novel kappa-opioid receptor agonist ameliorates atopic dermatitis
    Schneeweiss, M.
    Luediger, A.
    Chartolani, N.
    Soeberdt, M.
    Knie, U.
    Luger, T. A.
    Abels, C.
    Loser, K.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E47 - E47